Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 29.14% is 68% above its 5-year average of 17.31%, around the middle of its 5-year range (-237.85%–315.35%).
39.56% below its 12-month average of 48.21%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -6.43%.
EBITDA MARGIN
29.14%
EBITDA MARGIN AVG TTM
48.21%
EBITDA MARGIN AVG 3Y
-16.88%
EBITDA MARGIN AVG 5Y
17.31%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-39.56%
CURRENT VS 3Y AVG
+272.62%
CURRENT VS 5Y AVG
+68.35%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Maravai LifeSciences Holdings, Inc.
Market Cap
$2.17B
EBITDA Margin
29.14%
TTM Avg
48.21%
3Y Avg
-16.88%
5Y Avg
17.31%
Market Cap
$2.14B
EBITDA Margin
3.14%
TTM Avg
1.36%
3Y Avg
-82.25%
5Y Avg
-109.56%
Market Cap
$2.24B
EBITDA Margin
-37.02%
TTM Avg
-37.02%
3Y Avg
-37.02%
5Y Avg
-37.02%
Market Cap
$2.11B
EBITDA Margin
-4149.30%
TTM Avg
-2232.68%
3Y Avg
-1779.77%
5Y Avg
-1779.77%
Market Cap
$2.11B
EBITDA Margin
10.90%
TTM Avg
10.48%
3Y Avg
9.90%
5Y Avg
9.38%
Market Cap
$2.07B
EBITDA Margin
-512.27%
TTM Avg
-49559.94%
3Y Avg
-46888.38%
5Y Avg
-33454.98%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maravai LifeSciences Holdings, Inc. (MRVI) | $2.17B | 29.14% | 48.21% | -16.88% | 17.31% |
| Pharvaris N.V. (PHVS)vs › | $2.17B | N/A | N/A | N/A | N/A |
| GeneDx Holdings Corp. (WGS)vs › | $2.14B | 3.14% | 1.36% | -82.25% | -109.56% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.24B | -37.02% | -37.02% | -37.02% | -37.02% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | -4149.30% | -2232.68% | -1779.77% | -1779.77% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 10.90% | 10.48% | 9.90% | 9.38% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.10B | N/A | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.08B | 19.79% | 20.20% | -178.47% | -247.76% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.07B | -512.27% | -49559.94% | -46888.38% | -33454.98% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -18934.67% | -10834.15% | -7159.00% | -5150.48% |
Gross Margin
18.0%
EBITDA Margin
29.1%
Operating Margin
-3.6%
Net Margin
-37.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -6.43% |
| 2026-03-31 | 23.47% |
| 2025-12-31 | 16.03% |
| 2025-09-30 | 315.35% |
| 2025-06-30 | -107.37% |
| 2025-03-31 | -73.11% |
| 2024-12-31 | -41.85% |
| 2024-09-30 | -237.85% |
| 2024-06-30 | 6.86% |
| 2024-03-31 | -7.96% |
| 2023-12-31 | 7.86% |
| 2023-09-30 | -3.47% |
| 2023-06-30 | 0.27% |
| 2023-03-31 | 17.01% |
| 2022-12-31 | 58.26% |
| 2022-09-30 | 66.30% |
| 2022-06-30 | 78.11% |
| 2022-03-31 | 72.30% |
| 2021-12-31 | 67.64% |
| 2021-09-30 | 79.77% |
| 2021-06-30 | 75.17% |
| 2021-03-31 | 65.78% |
| 2020-12-31 | 37.79% |
| 2020-09-30 | 59.63% |
| 2020-06-30 | 31.12% |
| 2020-03-31 | 81.56% |
| 2019-12-31 | 22.03% |
